Blood Cancer United to Present Landmark Research at 2025 ASH Annual Meeting

Blood Cancer United Showcases Groundbreaking Research at 2025 ASH Annual Meeting

Blood Cancer United®, previously known as The Leukemia & Lymphoma Society, has announced that it will present significant new research findings at the upcoming American Society of Hematology (ASH) Annual Meeting, taking place from December 6 to 9, 2025. This event marks a critical opportunity to share advancements in treatment and care for patients battling blood cancers.

Lore Gruenbaum, Ph.D., the Chief Scientific Officer of Blood Cancer United, expressed enthusiasm about the upcoming presentations. She noted, "We are excited to see firsthand at the ASH Annual Meeting the scientific breakthroughs that provide life-changing benefits for more patients, helping to extend and improve their lives and move us closer to achieving durable remission for more patients with blood cancer."

The organization plans to present vital data derived from several sub-studies of its Beat AML® Master Clinical Trial and the Pediatric Acute Leukemia Master Clinical Trial (PedAL). Among the findings will be analyses from over 2,000 patients treated with venetoclax, which focus on integrating clinical and genomic features to enhance patient prognosis within clinical settings. This kind of research is essential, as it allows healthcare providers to better understand the individual needs of patients diagnosed with acute myeloid leukemia (AML).

In addition to this, Blood Cancer United will showcase new data related to the impact of mutations in RAS genes on the prognosis of AML patients with NPM1 mutations. A poster presentation will discuss an ongoing trial assessing the effectiveness of combining ficlatuzumab, a first-in-class anti-hepatocyte growth factor antibody, with azacitidine and venetoclax. Furthermore, an abstract from the PedAL trial aims to identify potential treatment optimizations for children suffering from AML.

The conference follows the recent FDA approval of ziftomenib for adults with advanced forms of AML harboring a mutation in the NPM1 gene. Blood Cancer United will also provide updates regarding the utilization of ziftomenib and other menin inhibitors. This will include two oral presentations concerning combination studies utilizing ziftomenib in conjunction with venetoclax and azacitidine for newly diagnosed and relapsed/refractory AML cases.

Overall, more than 50 abstracts will be presented by fifteen current and former partners of the Therapy Acceleration Program® (TAP), illustrating promising clinical results in various types of blood cancers, including myelodysplastic syndromes, large granular lymphocytic leukemia, and T-cell lymphoma, among others.

More importantly, the research financed through Blood Cancer United's various grants, including its Academic Research Grant Program, will review opportunities to enhance the quality of care for all blood cancer patients. Topics of interest will include the influence of travel and insurance status on patients’ access to care.

Experts and leaders from Blood Cancer United, including Dr. Gruenbaum, E. Anders Kolb, M.D., Ms. Gwen Nichols, and Ashley Yocum, Ph.D., will be available to discuss the findings and other studies presented at the meeting.

The organization's mission to cure blood cancer and enhance the quality of life for affected patients and their families continues to drive forward. Since its establishment in 1949, Blood Cancer United has evolved to provide support that caters to the needs of all blood cancer patients, encompassing over 100 different forms of the disease.

With a commitment to investing over $2 billion in vital research initiatives, Blood Cancer United aims to bolster survival rates and advocate for accessible, affordable healthcare across the board.

For more information on Blood Cancer United's extensive research portfolio, interested parties can visit bloodcancerunited.org/research for further details on key presentations and findings from the ASH Annual Meeting.